Skip to main content

Table 1 Characteristics of patients and tumors in the primary study cohort and validation cohorts relative to pCR status

From: Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers

Characteristic

Primary study populationa

(n = 1166)

HaBCSb

(n = 338)

GeparSeptob

paclitaxel

(n = 392)

GeparSeptob

nab-pacitaxel

(n = 389)

GeparOctob

ETC

(n = 269)

No pCR

(n = 893)

pCR

(n = 273)

No pCR

(n = 247)

pCR

(n = 91)

No pCR

(n = 325)

pCR

(n = 67)

No pCR

(n = 280)

pCR

(n = 109)

No pCR

(n = 181)

pCR

(n = 88)

Age (years)

52.9 (11.5)

50.3 (12.4)

54.9 (12.4)

50.5 (11.2)

49.2 (11.0)

48.5 (11.2)

49.7 (10.2)

50.3 (9.5)

49.2 (10.8)

47.0 (10.2)

BMI (kg/m2)

26.4 (5.2)

25.1 (4.9)

25.1 (2.3)

25.4 (2.6)

26.5 (5.5)

25.9 (5.6)

26.6 (5.5)

26.0 (5.2)

26.2 (5.1)

26.6 (5.5)

Tumor stage

          

cT1

185 (20.7)

110 (40.3)

36 (14.6)

23 (25.3)

96 (29.2)

31 (46.3)

79 (28.2)

52 (47.7)

64 (35.4)

36 (40.9)

cT2

567 (63.5)

148 (54.2)

179 (72.5)

62 (68.1)

177 (54.5)

34 (50.7)

158 (56.4)

50 (54.9)

90 (49.7)

48 (43.5)

cT3

48 (5.4)

5 (1.8)

15 (6.1)

4 (4.4)

32 (9.8)

1 (1.5)

24 (8.6)

2 (1.8)

20 (11.0)

3 (3.4)

cT4

93 (10.4)

10 (3.7)

17 (6.9)

2 (2.2)

20 (6.2)

1 (1.5)

19 (6.8)

5 (4.6)

7 (3.9)

1 (1.1)

Grade

          

Grade 1

36 (4.0)

2 (0.7)

3 (1.2)

0 (0.0)

7 (2.2)

1 (1.5)

8 (2.9)

4 (3.7)

2 (1.1)

1 (1.1)

Grade 2

401 (44.9)

34 (12.5)

71 (28.7)

6 (6.6)

141 (43.4)

15 (22.4)

138 (49.3)

27 (24.8)

62 (34.3)

4 (4.5)

Grade 3

456 (51.1)

237 (86.8)

173 (70.0)

85 (93.4)

177 (54.5)

51 (76.1)

134 (47.9)

78 (71.6)

117 (64.6)

83 (94.3)

Lymph node status

          

cN0

389 (43.6)

159 (58.2)

137 (55.5)

60 (65.9)

209 (64.3)

49 (73.1)

173 (61.8)

80 (73.4)

105 (58.0)

66 (75.0)

cN + 

504 (56.4)

114 (41.8)

110 (44.5)

31 (34.1)

116 (35.7)

18 (26.9)

107 (38.2)

29 (26.6)

76 (32.0)

22 (25.0)

Tumor type

          

Ductal

634 (71.0)

193 (70.7)

221 (89.5)

87 (95.6)

275 (84.6)

53 (79.1)

233 (83.2)

92 (84.4)

155 (85.6)

63 (71.6)

Lobular

94 (10.5)

5 (1.8)

17 (6.9)

1 (1.1)

18 (6.6)

2 (3.0)

22 (7.9)

1 (0.9)

0 (0.0)

0 (0.0)

Other

165 (18.5)

75 (27.5)

9 (3.6)

3 (3.3)

32 (9.4)

12 (17.9)

25 (8.9)

16 (14.7)

26 (14.4)

25 (28.4)

ER (continuous, 0%–100%)

55.7 (39.8)

12.9 (28.4)

55.5 (42.5)

9.7 (24.7)

52.4 (45.3)

18.5 (34.8)

60.8 (44.4)

15.6 (31.8)

28.8 (43.1)

3.0 (14.7)

ER (categorical)

          

Negative (< 1%)

246 (27.5)

199 (72.9)

74 (30.0)

73 (80.2)

113 (34.8)

44 (65.7)

111 (39.6)

82 (75.2)

118 (65.2)

82 (93.2)

Positive (≥ 1%)

647 (72.5)

74 (27.1)

173 (70.0)

18 (19.8)

212 (65.2)

23 (34.3)

169 (60.4)

27 (24.8)

63 (34.8)

6 (6.8)

PgR (continuous, 0%–100%)

34.1 (36.4)

4.4 (14.8)

34.8 (36.4)

6.2 (19.4)

28.7 (36.5)

8.3 (21.5)

33.1 (37.8)

7.9 (19.9)

14.0 (27.9)

1.3 (8.8)

PgR (categorical)

          

Negative (< 1%)

332 (37.2)

225 (82.4)

102 (41.3)

77 (84.6)

142 (43.7)

48 (71.6)

111 (39.6)

82 (75.2)

125 (69.1)

84 (95.5)

Positive (≥ 1%)

561 (62.8)

48 (17.6)

145 (58.7)

14 (15.4)

183 (56.3)

19 (28.4)

169 (60.4)

27 (24.8)

56 (30.9)

4 (4.5)

Ki-67 (continuous, 0%–100%)

37.9 (25.0)

62.9 (21.0)

38.4 (22.4)

58.5 (23.5)

38.6 (25.4)

62.0 (23.1)

37.5 (25.2)

58.1 (25.0)

52.0 (21.3)

66.4 (18.5)

Ki-67 (categorical)

          

Negative (< 14%)

164 (18.4)

4 (1.5)

14 (5.7)

1 (1.1)

53 (16.3)

2 (3.0)

53 (18.9)

5 (4.6)

5 (2.8)

0 (0.0)

Positive (≥ 14%)

729 (81.6)

269 (98.5)

233 (94.3)

90 (98.9)

272 (83.7)

65 (97.0)

227 (81.1)

104 (95.4)

176 (97.2)

88 (100)

Molecular subtypec

          

Luminal A–like

388 (43.4)

17 (6.2)

68 (27.5)

4 (4.4)

122 (37.5)

10 (14.9)

129 (46.1)

14 (12.8)

33 (18.2)

0 (0.0)

Luminal B–like

279 (31.2)

64 (23.4)

109 (44.1)

21 (23.1)

104 (32.0)

21 (31.3)

82 (29.3)

28 (25.7)

35 (19.3)

7 (8.0)

Triple-negative

226 (25.3)

192 (70.3)

70 (28.3)

66 (72.5)

99 (30.5)

36 (53.7)

69 (24.6)

67 (61.5)

113 (62.4)

81 (92.0)

Chemotherapyd

          

Anthracycline

673 (75.4)

131 (48.0)

208 (86.7)

71 (81.6)

325 (100.0)

67 (100.0)

280 (100.0)

109 (100.0)

181 (100.0)

88 (100.0)

Platinum

132 (14.8)

130 (47.6)

17 (7.1)

15 (17.2)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Taxane

721 (80.7)

248 (90.8)

228 (94.2)

86 (98.9)

325 (100.0)

67 (100.0)

280 (100.0)

109 (100.0)

181 (100.0)

88 (100.0)

  1. Mean and SD are shown for continuous characteristics; frequency and percentage are shown for categorical characteristics
  2. BMI, body mass index; ER, estrogen receptor (expression); ETC, high-dose epirubicin, taxane, and cyclophosphamide; HaBCS, Hannover breast cancer study; pCR, pathological complete response; PgR, progesterone receptor (expression); SD, standard deviation
  3. aComplete information was available for 94.3% (n = 1100) of the patients. The percentage of missing values for each variable was below 0.5%, with the exception of BMI (2.8%) and grading (2.0%). Missing values were imputed as described above
  4. bMissing values were substituted by best guesses (ie, median values, most common categories)
  5. cLuminal A–like tumors are hormone receptor–positive (ER-positive or PgR-positive) with grade 1 or 2; luminal B–like tumors are hormone receptor–positive with grade 3; triple-negative tumors are ER-negative and PgR-negative
  6. dThe sum of the percentages is > 100 because some patients received combined chemotherapy
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us